

*(Use as many sheets as necessary)*

**SHEET 1 of 2**

**Complete if Known**

Application Number	09/936,377
--------------------	------------

<b>Filing Date</b>	<b>February 26, 2002</b>
--------------------	--------------------------

First Named Inventor	Catherine DEFRENNE
----------------------	--------------------

Art Unit	1645
----------	------

Examiner Name	Padmavathi Baskar
---------------	-------------------

Attorney Docket No.	GSKB-109US
---------------------	------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (If known)				
/PB/		WO 00/22430 A3	04/20/2000	Chiron Corp.		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
Examiner Signature	/Padmavathi Baskar/			Date Considered	10/09/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/936,377
Filing Date	February 26, 2002
First Named Inventor	Catherine DEFRENNE
Art Unit	1645
Examiner Name	Padmavathi Baskar
Attorney Docket No.	GSKB-109US

SHEET 2 of 3

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/PB/		"Selection of Immunogenic Peptides for Antisera Production," <i>Current Protocols in Immunology</i> , John Wiley & Sons, 1991, units 9.3.1-9.3.5.	<input type="checkbox"/>
/PB/		GEYSEN et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Nat. Acad. Sci. USA</i> , July 1984, Vol. 81, pp. 3998-4002.	<input type="checkbox"/>
/PB/		REECE et al., "Scanning for T helper epitopes with human PBMC using pools of short synthetic peptides," <i>Journal of Immunological Methods</i> , 1994, Vol. 172, No. 2, pp. 241-254.	<input type="checkbox"/>
/PB/		REECE et al., "Mapping the Major Human T Helper Epitopes of Tetanus Toxin," <i>The Journal of Immunology</i> , 1993, Vol. 151, pp. 6175-6184.	<input type="checkbox"/>
/PB/		"Synthesis of Multiple Peptides on Plastic Pins," <i>Current Protocols in Immunology</i> , John Wiley & Sons, 1997, units 9.7.1-9.7.19.	<input type="checkbox"/>
/PB/		NIMAN, et al., "Generation of protein-reactive antibodies by short peptides is an event of high frequency: Implications for the structural basis of immune recognition," <i>Proc. Natl. Acad. Sci. USA</i> , August 1983, Vol. 80, pp. 4949-4953.	<input type="checkbox"/>
/PB/		DILLNER et al., "Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen," August 1984, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 81, pp. 4652-4656.	<input type="checkbox"/>
/PB/		SALI et al., "Three-dimensional Models of four Mouse Mast Cell Chymases," <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 12, April 25, 1993, pp. 9023-9034.	<input type="checkbox"/>
/PB/		TETTELIN et al., "Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58," <i>Science</i> , Vol. 287, March 10, 2000, pp. 1809-1815.	<input type="checkbox"/>
/PB/		ZHOU et al., "On the origin of membrane vesicles in Gram-negative bacteria," <i>Fems Microbiology Letter</i> , 163, 1998, pp. 223-238.	<input type="checkbox"/>
/PB/		SHINNICK et al., "Synthetic Peptide Immunogens as Vaccines," <i>Annual Review Microbiology</i> , 1983, Vol. 37, pp. 425-446.	<input type="checkbox"/>
/PB/		GEYSEN et al., "Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82, January 1985, pp. 178-182.	<input type="checkbox"/>
/PB/		ROITT et al., "The Structures of Antigens," <i>Immunology</i> , 3d Edition, 1993, units 7.7-7.8.	<input type="checkbox"/>
Examiner Signature	/Padmavathi Baskar/		Date Considered 10/09/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	09/936,377
	Filing Date	February 26, 2002
	First Named Inventor	Catherine DEFRENNE
	Art Unit	1645
	Examiner Name	Padmavathi Baskar
<b>SHEET 3 of 3</b>	Attorney Docket No.	GSKB-109US

<b>NON-PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published</b>	<b>T<sup>2</sup></b>		
/PB/		PEETERS et al., "Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesical vaccine," <i>Vaccine</i> , Vol. 14, No. 10, 1996, pp. 1009-1015.	<input type="checkbox"/>		
/PB/		CLAASSEN et al., "Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine," <i>Vaccine</i> , Vol. 14, No. 10, 1996, pp. 1001-1008.	<input type="checkbox"/>		
/PB/		FREDRIKSEN et al., "Production, characterization and control of MenB-vaccine "Folkehelse": an outer membrane vesicle vaccine against group B meningococcal disease," <i>NIPH Annals</i> , Vol. 14, No.2, December 1991, pp. 67-80.	<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		
			<input type="checkbox"/>		

<b>Examiner Signature</b>	/Padmavathi Baskar/	<b>Date Considered</b>	10/09/2008
---------------------------	---------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*